Navigation Links
Alzheimer's risk gene disrupts brain's wiring 50 years before disease hits
Date:5/13/2011

What if you were told you carried a gene that increases your risk for Alzheimer's disease? And what if you were told this gene starts to do its damage not when you're old but when you're young?

Brace yourself.

Scientists know there is a strong genetic component to the development of late-onset Alzheimer's. In 1993, researchers discovered a gene known as ApoE4 carried by about a quarter of us that triples the risk for getting Alzheimer's. In 2009, three more risky genes were discovered, and one of them, called clusterin, or CLU, was found to up the risk of getting Alzheimer's by another 16 percent.

But nobody could explain what the CLU gene actually did. Now, UCLA researchers know, and the explanation is a doozy: This risk gene begins to damage your brain a full 50 years before people normally get Alzheimer's.

In the current online edition of the Journal of Neuroscience, Paul Thompson, a UCLA professor of neurology, and his colleagues report that the C-allele of the CLU gene (an allele is one of two or more forms of a gene), which is possessed by 88 percent of Caucasians, impairs the development of myelin, the protective covering around the neuron's axons in the brain, making it weaker and more vulnerable to the onset of Alzheimer's much later in life.

The researchers scanned the brains of 398 healthy adults ranging in age from 20 to 30 using a high-magnetic-field diffusion scan (called a 4-Tesla DTI), a newer type of MRI that maps the brain's connections. They compared those carrying a C-allele variant of the CLU gene with those who had a different variant, the CLU T-allele.

They found that the CLU-C carriers had what brain-imaging researchers call lower "fractional anisotropy" a widely accepted measure of white-matter integrity in multiple brain regions, including several known to degenerate in Alzheimer's. In other words, young, healthy carriers of the CLU-C gene risk variant showed a distinct profile of lower white matter integrity that may increase vulnerability to developing the disease later in life.

The discovery of what this gene does is interesting on several levels, said Thompson, the senior author of the study.

"For example, Alzheimer's has traditionally been considered a disease marked by neuronal cell loss and widespread gray-matter atrophy," he said. "But degeneration of myelin in white-matter fiber pathways is more and more being considered a key disease component and another possible pathway to the disease, and this discovery supports that."

Thompson said four things are surprising with the discovery of this gene's function:

  1. This risk gene damages your brain a full 50 years before people normally get Alzheimer's. The damage can be seen on an MRI scan, but there are no symptoms yet.

  2. It's now known what this mysterious gene does namely, make your brain wiring vulnerable to attack by impairing the wiring before any senile plaques or tangles develop.

  3. Rather than being a gene that few people have, a whopping 88 percent of Caucasians have it. "So I guess you could say the other 12 percent have an 'Alzheimer's resistance gene' that protects their brain wiring," said Thompson, who is also a member of UCLA's Laboratory of Neuro Imaging and the UCLA Brain Research Institute.

  4. Finally, he said, knowing the role of this gene is useful in predicting a person's risk of the disease and in seeing if you can step in and protect the brain in the 50-year time window you have before the disease begins to develop.

Of course, the obvious question is if most of us have this "bad" gene, why isn't Alzheimer's rampant in young people?

Less myelination in CLU-C carriers may not translate into poorer cognition in youth, said Thompson, because the brain can compensate. "The brain has a lot of built in redundancy miles and miles of brain connections," he said. Still, he said, with the passage of time and when exacerbated by other factors, such as normal neuron death as we age and plaque and tangle development in the early stages of Alzheimer's reduced myelin integrity could facilitate cognitive impairment.

"So it's unlikely we are seeing the earliest possible signs of Alzheimer's-associated brain changes in these young people," Thompson said. "It's more likely the reduced fiber integrity represents an early developmental vulnerability that may reduce brain resilience to later Alzheimer's disease pathology. Inn other words, its mechanism of action may not be part of the classic Alzheimer's pathways that lead to abnormal amyloid plaque and neurofibrillary tangle accumulation in the brain."

The mapping of structural brain differences in those at genetic risk for Alzheimer's disease is crucial for evaluating treatment and prevention strategies, Thompson said. Once identified, brain differences can be monitored to determine how lifestyle choices influence brain health and disease risk.

"We know that many lifestyle factors, such as regular exercise and a healthful diet, may reduce the risk of cognitive decline, particularly in those genetically at risk for Alzheimer's, so this reminds us how important that is," he said.


'/>"/>

Contact: Mark Wheeler
mwheeler@mednet.ucla.edu
310-794-2265
University of California - Los Angeles
Source:Eurekalert

Related biology news :

1. Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development
2. In lung cancer, silencing one crucial gene disrupts normal functioning of genome
3. Stress disrupts human thinking, but the brain can bounce back
4. Artificial light at night disrupts cell division
5. Why the biological clock? Penn study says aging reduces centromere cohesion, disrupts reproduction
6. Old and young brains rely on different systems to remember emotional content
7. Rice University psychologist finds womens brains recognize, encode smell of male sexual sweat
8. Our brains make their own marijuana: Were all pot heads deep inside
9. Snakes and how they helped our big brains evolve
10. Monkey brains signal the desire to explore
11. Scientists remove amyloid plaques from brains of live animals with Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2016)... Jan. 22, 2016 ... of the "Global Biometrics Market in ... offering. --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ... "Global Biometrics Market in Retail Sector 2016-2020" ... --> Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ...
(Date:1/20/2016)... A market that just keeps on growing. ... explosion in genomics knowledge. Learn all about it in ... of dynamic trends are pushing market growth and company ... pharmacogenomics - pathogen evolution - next generation sequencing - ... understanding of the role of genetic material in Disease ...
(Date:1/20/2016)... Calif. , Jan. 20, 2016  Synaptics ... of human interface solutions, today announced sampling of ... solution for wearables and small screen applications including ... as printers. Supporting round and rectangular shapes, as ... offers excellent performance with moisture on screen, while ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016  In the pharmaceutical ... for a host of launch activities including the identification ... this launch activity is especially high in the oncology ... Best Practices and the Role of Medical Affairs ... companies focused on oncology therapies find better ways to ...
(Date:2/5/2016)... , February 5, 2016 Amarantus ... biotechnology company focused on developing products for Regenerative Medicine, ... Rare Pediatric Disease Designation (RPDD) from the US Food ... with MANF. MANF was previously granted orphan drug designation ... --> Amarantus BioScience Holdings, Inc. (OTCQB: ...
(Date:2/4/2016)... ... February 04, 2016 , ... Morf Media Inc ... an interactive FDA compliance training course, Writing Effective SOPs ... accredited interactive course on Morf Playbook—now conveniently available on smartphones and PCs--provides step ...
(Date:2/4/2016)... 2016  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), ... Edward Lanphier , Sangamo,s president and chief executive ... Sangamo,s ZFP Therapeutic ® development programs and an ... ET on Thursday, February 11, 2016, at the Leerink ... conference is being held in New York ...
Breaking Biology Technology: